Page last updated November 9, 2026
Study Design: Intervention Trial
PCORnet Infrastructure: Common Data Model (CDM), Single IRB, Patient partners or engagement
Principal Investigator: Tariq Shafi, Jenny Flythe, Laura Dember, and Tom Carton
Institution: Baylor Scott & White Health (BSWH)
PCORnet® Network Partner: REACHnet
Funder: Patient-Centered Outcomes Research Institute (PCORI); (Project webpage)
Funding Date: 2026
Study Duration: 2026 – 2031
Participating PCORnet® Clinical Research Networks: REACHnet
Therapeutic Area: Nephrology, Cardiovascular, Endocrinology, Healthcare Delivery, Health Disparities
Status: Not yet recruiting
Research Question(s):
Does adding a sodium-glucose cotransporter-2 (SGLT2) inhibitor to standard treatment with a renin-angiotensin system (RAS) inhibitor help adults with advanced chronic kidney disease live longer, delay the need for dialysis or kidney transplantation, reduce heart and kidney complications, and maintain quality of life compared with treatment with a RAS inhibitor alone?